Pharmacokinetic Study of DYANAVEL XR (Amphetamine) Extended-release Oral Suspension, in Children Aged 4 to 5 Years

NCT03610464 · clinicaltrials.gov ↗

PHASE4

Phase

COMPLETED

Status

5

Enrollment

INDUSTRY

Sponsor class

Conditions

Attention Deficit Hyperactivity Disorder

Interventions

DRUG: Amphetamine Extended Release Suspension [Dyanavel]

Sponsor

Tris Pharma, Inc.